Biosimilars

Pharmalot Ed Silverman

U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition

Pharmalot Ed Silverman

Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible

Pharmalot Ed Silverman

AbbVie settles litigation with another drug maker over a biosimilar version of Humira

Pharmalot Ed Silverman

FDA approves an interchangeable biosimilar version of Humira, but health care savings are dubious

Opinions+ Pierre Bourdage

Three steps toward creating a functioning U.S. biosimilars market

Pharmalot Ed Silverman

AbbVie accuses a company of recruiting an employee in order to steal Humira secrets

Pharmalot Ed Silverman

Once again, the viability of the U.S. biosimilar market is thrown into question

Pharmalot Ed Silverman

In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition

Pharmalot Ed Silverman

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Pharmalot Ed Silverman

Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs

Pharmalot Ed Silverman

Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks

Pharmalot Ed Silverman

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Pharmalot Ed Silverman

Large employers could have saved money if more biosimilars had been prescribed

First Opinion Carol Lynch

Biosimilars could disappear if the Supreme Court overturns the ACA

First Opinion Sean McGowan

Five years on, biosimilars need support from all health care players

First Opinion Leah Christl

From bench to bedside, biologics require excellence at every stage

Pharmalot Ed Silverman

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Business Matthew Herper

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

Pharmalot Ed Silverman

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Politics Lev Facher

Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Pharmalot Ed Silverman

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

Pharmalot Ed Silverman

More hospital drug spending is going toward cancer immunotherapies

Pharmalot Ed Silverman

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

First Opinion Juliana Reed

Some bipartisan support for biosimilars is good. More would be better

First Opinion Jessica Sagers and Peter Kolchinsky

Biosimilars

Most Read

Biosimilars competition helps patients more than generic competition

AbbVie loses a lawsuit over Humira trade secrets it claimed were stolen

FDA’s naming rule for biosimilars has undermined Congress and health care

Virtual Event: The evolving landscape for biosimilars

Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch

The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means

FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?

FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug

All Coverage

U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition

Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible

AbbVie settles litigation with another drug maker over a biosimilar version of Humira

FDA approves an interchangeable biosimilar version of Humira, but health care savings are dubious

Three steps toward creating a functioning U.S. biosimilars market

AbbVie accuses a company of recruiting an employee in order to steal Humira secrets

Once again, the viability of the U.S. biosimilar market is thrown into question

In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs

Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Large employers could have saved money if more biosimilars had been prescribed

Biosimilars could disappear if the Supreme Court overturns the ACA

Five years on, biosimilars need support from all health care players

From bench to bedside, biologics require excellence at every stage

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

More hospital drug spending is going toward cancer immunotherapies

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

Some bipartisan support for biosimilars is good. More would be better

Booker-Sanders-Harris drug affordability bureau could be brilliant

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day